Press Releases
You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
Enrollment of adult patients started at the Bispebjerg University Hospital in Copenhagen in February 2022, while teenage patients have been enrolled at...
Extensive new preclinical study significantly increases the Translatability of Asarina Pharma’s findings on key stress mechanism implicated in Tourette Syndrome and OCD
2022-10-06 08:30
Regulatory
A new study, the fourth and most comprehensive in a series of four (1), reconfirms that acute stress increases the overproduction of the powerful neurosteroid...
Asarina Pharma AB: new US CDC study suggests prevalence of Tourette significantly higher than previously thought
2022-09-05 13:24
A new study – ‘Estimating the number of people with Tourette syndrome and persistent tic disorder in the United States’ - has been published...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME CEO Peter Nordkild: “If full clinical development is successful, Sepranolone will be the...
Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen
2022-06-23 11:15
Regulatory
On 31 May 2021, Asarina Pharma announced by press release that the Company had signed a convertible loan agreement with ÖSS (the “Loan Agreement”)...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/...
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2021...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that...
Asarina Pharma’s Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the clinical trial...